Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1988-9-20
|
pubmed:abstractText |
A dawn rise of plasma glucose (PG) and/or insulin, the 'dawn phenomenon', has been commonly reported in treated diabetic patients and normal subjects. To evaluate the effect of treatment on this phenomenon in non-insulin-dependent diabetics (NIDDMs), PG, C peptide, immunoreactive insulin (IRI), growth hormone (GH), cortisol, epinephrine, and norepinephrine were measured hourly between 24.00 and 09.00 h in 17 newly diagnosed untreated NIDDMs (group 1). The study was repeated in 11 patients after a year of treatment (group 2). The PG levels did not change significantly at any time from 03.00 to 08.00 h in group 1 but increased continuously from 6.7 +/- 0.5 mmol/l at 04.00 h to 7.8 +/- 0.5 mmol/l at 08.00 h (P less than 0.01) in group 2. IRI and C peptide decreased significantly after 07.00 h in both groups. GH and catecholamine changes were similar in group 1 and group 2. Cortisol levels showed a nadir at 02.00 h and a peak after 07.00 h in both groups. Our results demonstrate no dawn rise of mean PG, IRI and C peptide in newly diagnosed untreated NIDDMs but a significant rise of PG in the early morning period in NIDDMs after a year of treatment with diet alone and diet plus sulphonylureas. Therefore other factors such as treatment and/or duration of the diabetes may play an important role in the pathogenesis of the dawn phenomenon.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/C-Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Epinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrocortisone,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0168-8227
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
19
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
37-44
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3042344-Blood Glucose,
pubmed-meshheading:3042344-C-Peptide,
pubmed-meshheading:3042344-Circadian Rhythm,
pubmed-meshheading:3042344-Diabetes Mellitus, Type 2,
pubmed-meshheading:3042344-Epinephrine,
pubmed-meshheading:3042344-Female,
pubmed-meshheading:3042344-Follow-Up Studies,
pubmed-meshheading:3042344-Growth Hormone,
pubmed-meshheading:3042344-Hormones,
pubmed-meshheading:3042344-Humans,
pubmed-meshheading:3042344-Hydrocortisone,
pubmed-meshheading:3042344-Insulin,
pubmed-meshheading:3042344-Male,
pubmed-meshheading:3042344-Middle Aged,
pubmed-meshheading:3042344-Norepinephrine
|
pubmed:year |
1988
|
pubmed:articleTitle |
Non-insulin-dependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation.
|
pubmed:affiliation |
Department of Medicine, University of Wales College of Medicine, Cardiff, U.K.
|
pubmed:publicationType |
Journal Article
|